drugset / Trial / NCT07131280

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

NCT07131280

RandomizedParallel-groupOpen-labelTreatment

Summary

Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.

Timeline

Start
2025-09
Primary completion
2031-07
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 40 ug Subcutaneous
Subject G-CSF Protein / enzyme biologic 5 ug/kg Subcutaneous

Indications